<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03376230</url>
  </required_header>
  <id_info>
    <org_study_id>2009_13</org_study_id>
    <secondary_id>2010-A00056-33</secondary_id>
    <nct_id>NCT03376230</nct_id>
  </id_info>
  <brief_title>Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease</brief_title>
  <acronym>CHIMICI</acronym>
  <official_title>Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammatory Bowel Diseases (IBD) including Crohn's disease and ulcerative colitis are&#xD;
      multifactorial diseases leading to chronic inflammation of intestinal mucosa. Their etiology&#xD;
      is still unknown. Recently, major advances in the understanding of their pathophysiology have&#xD;
      allowed to define them as heterogenic polygenic diseases, occurring in genetically&#xD;
      susceptible patients. However, the whole genetic susceptibility does not explain the&#xD;
      development of IBD and several data argue in favor of the involvement of environmental&#xD;
      factors, which remain to be identified.&#xD;
&#xD;
      The aims of this clinical trial are:&#xD;
&#xD;
        1. As main objective: To determine the effects of environmental pollutants on intestinal&#xD;
           homeostasis and particularly on inflammatory process and endoplasmic reticulum stress.&#xD;
&#xD;
        2. As secondary objective, to assess in human the genetic susceptibility of intestinal&#xD;
           mucosa to environmental chemical compounds (I.e. xenobiotics), its interindividual&#xD;
           variability, and its potential involvement in the pathogenesis of IBD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    not enough recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">February 2010</start_date>
  <completion_date type="Actual">January 24, 2019</completion_date>
  <primary_completion_date type="Actual">January 24, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of inflammatory response of biopsies to pollutants between the 3 groups of patients.</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of expression pattern of genes involved in xenobiotics detoxification in intestinal mucosa in between the 3 groups of patients.</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Study of molecular origin and consequences of the genetic variability observed.</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">148</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Control patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Crohn's disease patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulcerative colitis patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collect of blood, urines, and intestinal biopsies</intervention_name>
    <arm_group_label>Control patients</arm_group_label>
    <arm_group_label>Crohn's disease patients</arm_group_label>
    <arm_group_label>Ulcerative colitis patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Intestinal mucosal biopsies Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        600 divided into 3 groups:&#xD;
&#xD;
          -  200 patients with ulcerative colitis&#xD;
&#xD;
          -  200 patients with Crohn's disease&#xD;
&#xD;
          -  200 control patients not suffering from inflammatory bowel disease and whose follow-up&#xD;
             requires the realization of a coloscopy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who are at least 18 years old&#xD;
&#xD;
          2. Has Crohn's disease or ulcerative colitis, diagnosed, confirmed by radiological and /&#xD;
             or endoscopic examination within 4 years or &quot;Control&quot; patient not suffering from&#xD;
             inflammatory bowel disease (patient with abdominal pain and / or persistent diarrhea,&#xD;
             or patient requiring coloscopy for cancer of the digestive tract diagnosis)&#xD;
&#xD;
          3. Patients requiring coloscopy as part of their medical follow-up&#xD;
&#xD;
          4. Social insured.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant women&#xD;
&#xD;
          2. Breastfeeding women&#xD;
&#xD;
          3. People in emergency&#xD;
&#xD;
          4. Persons unable to understand, read and / or sign informed consent&#xD;
&#xD;
          5. Patients who recently had an intercurrent episode (eg recent diarrhea ...)&#xD;
&#xD;
          6. Persons deprived of their liberty&#xD;
&#xD;
          7. Persons protected by a legal protection status&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Desreumeaux, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU, HÃ´pital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>February 12, 2019</last_update_submitted>
  <last_update_submitted_qc>February 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Environmental risk factors</keyword>
  <keyword>Xenobiotic detoxification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

